Phosphoinositide 3-kinase inhibitor

AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma

Retrieved on:

Thursday, July 8, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer treatments, Clinical medicine, Chemical compounds, Kidney cancer, Antineoplastic drugs, Renal cell carcinoma, Orphan drugs, Tivozanib, P110δ, Phosphoinositide 3-kinase inhibitor, FOTIVDA® (tivozanib), AVEO Pharmaceuticals, Inc., FOTIVDA® (TIVOZANIB), AVEO PHARMACEUTICALS, INC.

AVEO's management team will provide a brief company overview and discuss the market opportunity and launch strategy for FOTIVDA.

Key Points:

AVEO's management team will provide a brief company overview and discuss the market opportunity and launch strategy for FOTIVDA.
AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
FOTIVDA has been shown to significantly reduce regulatory T-cell production in preclinical models.1 FOTIVDA was discovered by Kyowa Kirin.
FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU

Retrieved on:

Monday, June 21, 2021

In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.

Key Points:

In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.
Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K- and PI3K- isoforms expressed in malignant B cells.
Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.
The clinical development program for Aliqopa also includes the Phase III study CHRONOS-4, evaluating Aliqopa in combination with standard immunochemotherapy in relapsed iNHL.

Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting

Retrieved on:

Friday, June 4, 2021

Branches of biology, Signal transduction, Clinical medicine, Medicine, Oncology, Drug discovery, Phosphoinositide 3-kinase inhibitor, Phosphoinositide 3-kinase, MTOR, Antineoplastic drugs, Quinolines, Dactolisib

Globally, there are no PI3K inhibitors that have been approved for the treatment of T cell lymphomas.

Key Points:

Globally, there are no PI3K inhibitors that have been approved for the treatment of T cell lymphomas.
Another clinical study of linperlisib was also presented at ASCO entitled "A phase Ib study of the PI3K inhibitor linperlisib in patients with advanced solid tumors".
"YL-13027 has demonstrated to be a safe and tolerable oral agent that is highly selective for TGFR1 over TGFR2.
Yingli Pharma is developing best-in-class and first-in-class oral investigational agents for the treatment of cancer, metabolic and autoimmune diseases.

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021

Retrieved on:

Monday, April 26, 2021

Clinical medicine, Medicine, CD135, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Leukemia, Protein kinase inhibitors, Lactams, Phosphoinositide 3-kinase inhibitor, Toralizumab

b"The live conference call can also be accessed through a link on the Investor Relations section of Aptose\xe2\x80\x99s website at https://www.aptose.com/investors/news - events/ir - calendar .

Key Points:

b"The live conference call can also be accessed through a link on the Investor Relations section of Aptose\xe2\x80\x99s website at https://www.aptose.com/investors/news - events/ir - calendar .
An archived version of the webcast along with a transcript will be available on the company\xe2\x80\x99s website for 30 days.\nThe press release, the financial statements and the management\xe2\x80\x99s discussion and analysis for the year and quarter ended March 31, 2021 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml .\nAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
The Company has two clinical- stage investigational products for hematologic malignancies: luxeptinib (formerly CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).\n"

Investigational Combination of Aliqopa® (copanlisib) and rituximab Significantly Increases Progression-Free Survival in Patients with Relapsed Indolent non-Hodgkin's Lymphoma

Retrieved on:

Saturday, April 10, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Drugs, Medicine, Antineoplastic drugs, Non-Hodgkin lymphoma, Orphan drugs, Copanlisib, Morpholines, Pyrimidines, Phosphoinositide 3-kinase inhibitor, Indolent lymphoma, Lymphoma

The results reported with the combination of copanlisib and rituximab suggest a potential advancement for patients with these diverse types of cancers.

Key Points:

The results reported with the combination of copanlisib and rituximab suggest a potential advancement for patients with these diverse types of cancers.
Of the relapsed iNHL patients included in the trial, 60% had FL, 20.7% marginal zone lymphoma (MZL), 10.9% small lymphocytic lymphoma (SLL) and 8.3% lymphoplasmacytoid lymphoma/Waldenstrm macroglobulinemia (LPL/WM).
Aliqopa (copanlisib) is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

Retrieved on:

Thursday, April 8, 2021

Drugs, Clinical medicine, Cancer treatments, CD135, Chronic lymphocytic leukemia, Protein kinase inhibitors, Acute myeloid leukemia, Tumors of the hematopoietic and lymphoid tissues, Leukemia, Bruton's tyrosine kinase, Antineoplastic drugs, Phosphoinositide 3-kinase inhibitor

The Aptose management team also will be hosting 1x1 meetings during the event.

Key Points:

The Aptose management team also will be hosting 1x1 meetings during the event.
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib (CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

Copanlisib, Sold Under the Brand Name Aliqopa: A Medication for the Treatment of Follicular Lymphoma - Global Drug Insight and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on:

Friday, April 2, 2021

Health, Pharmaceutical, Clinical medicine, Antineoplastic drugs, Medicine, Drugs, Copanlisib, Morpholines, Pyrimidines, Orphan drugs, Non-Hodgkin lymphoma, Follicular lymphoma, Lymphoma, Phosphoinositide 3-kinase inhibitor

Copanlisib, sold under the brand name Aliqopa is a medication for the treatment of Follicular lymphoma.

Key Points:

Copanlisib, sold under the brand name Aliqopa is a medication for the treatment of Follicular lymphoma.
Aliqopa is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
The Aliqopa- Drug Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition.
Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views.

Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma

Retrieved on:

Wednesday, March 31, 2021

Health sciences, Clinical medicine, Drugs, Orphan drugs, Breakthrough therapy, Antineoplastic drugs, Cancer treatments, Gene therapy, Lymphoma, Umbralisib, Phosphoinositide 3-kinase inhibitor

NMPA grants Breakthrough Therapy Designation to new medicines that are intended to treat serious conditions and where clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.

Key Points:

NMPA grants Breakthrough Therapy Designation to new medicines that are intended to treat serious conditions and where clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.
The BTD designation for Parsaclisib is based on the results observed in an ongoing Phase 2 study for the treatment of adults with relapsed or refractory FL being conducted in China (CTR2019239).
Parsaclisib is currently in Phase 2 pivotal trials for the treatment of adults with relapsed or refractory follicular or with marginal zone lymphoma.
In clinical studies, Parsaclisib has demonstrated potent and rapid anti-lymphoma activity with promising safety, efficacy, and persistence.

Idelalisib, Sold Under the Brand Name Zydelig: A Medication for the Treatment of Chronic Lymphocytic Leukaemia, Follicular Lymphoma - Global Drug Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on:

Tuesday, March 23, 2021

The Zydelig- Drug Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition.

Key Points:

The Zydelig- Drug Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition.
Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views.
Idelalisib, sold under the brand name Zydelig is a medication for the treatment of Chronic lymphocytic leukaemia, Follicular lymphoma.
Zydelig is indicated for the treatment of patients with relapsed follicular B-cell nonHodgkin lymphoma (FL) who have received at least two prior systemic therapies.

Global Uterine Cancer Clinical Trial Pipeline Report 2021-2025: Clinical Trial Stages, Drug Mechanism Classes, Company, Short-term Launch Highlights - ResearchAndMarkets.com

Retrieved on:

Tuesday, March 23, 2021

Health, Oncology, Health sciences, Drug discovery, Health, Clinical research, Pharmaceutical industry, Life sciences, Design of experiments, Clinical trial, Cancer, COVID-19 drug development, Phosphoinositide 3-kinase inhibitor

The "Global Uterine Cancer Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Global Uterine Cancer Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
Uterine Cancer Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Uterine Cancer market.
It covers emerging therapies for Uterine Cancer in active clinical development stages including early and late stage clinical trials.
The report provides Uterine Cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.